{"created":"2021-03-01T06:30:57.283127+00:00","id":23126,"links":{},"metadata":{"_buckets":{"deposit":"b326bbd0-ea5e-44fa-b158-844c58bd9eda"},"_deposit":{"id":"23126","owners":[],"pid":{"revision_id":0,"type":"depid","value":"23126"},"status":"published"},"_oai":{"id":"oai:nagoya.repo.nii.ac.jp:00023126","sets":["499:500:501"]},"author_link":["68545","68546"],"item_10_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-08","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"8","bibliographicPageEnd":"409","bibliographicPageStart":"401","bibliographicVolumeNumber":"28","bibliographic_titles":[{"bibliographic_title":"International Immunology","bibliographic_titleLang":"en"}]}]},"item_10_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"CD4+ regulatory T cells (Tregs) expressing the transcription factor FoxP3 are highly immune suppressive and play central roles in the maintenance of self-tolerance and immune homeostasis, yet in malignant tumors they promote tumor progression by suppressing effective antitumor immunity. Indeed, higher infiltration by Tregs is observed in tumor tissues, and their depletion augments antitumor immune responses in animal models. Additionally, increased numbers of Tregs and, in particular, decreased ratios of CD8+ T cells to Tregs among tumor-infiltrating lymphocytes are correlated with poor prognosis in various types of human cancers. The recent success of cancer immunotherapy represented by immune checkpoint blockade has provided a new insight in cancer treatment, yet more than half of the treated patients did not experience clinical benefits. Identifying biomarkers that predict clinical responses and developing novel immunotherapies are therefore urgently required. Cancer patients whose tumors contain a large number of neoantigens stemming from gene mutations, which have not been previously recognized by the immune system, provoke strong antitumor T-cell responses associated with clinical responses following immune checkpoint blockade, depending on the resistance to Treg-mediated suppression. Thus, integration of a strategy restricting Treg-mediated immune suppression may expand the therapeutic spectrum of cancer immunotherapy towards patients with a lower number of neoantigens. In this review, we address the current understanding of Treg-mediated immune suppressive mechanisms in cancer, the involvement of Tregs in cancer immunotherapy, and strategies for effective and tolerable Treg-targeted therapy.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10_identifier_60":{"attribute_name":"URI","attribute_value_mlt":[{"subitem_identifier_type":"DOI","subitem_identifier_uri":"http://doi.org/10.1093/intimm/dxw025"},{"subitem_identifier_type":"HDL","subitem_identifier_uri":"http://hdl.handle.net/2237/25320"}]},"item_10_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Oxford University Press","subitem_publisher_language":"en"}]},"item_10_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1093/intimm/dxw025","subitem_relation_type_select":"DOI"}}]},"item_10_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"This is a pre-copyedited, author-produced version of an article accepted for publication in [International Immunology] following peer review. The version of record [International Immunology. v.28, n.8, 2016, p.401-409] is available online at: http://doi.org/10.1093/intimm/dxw025.","subitem_rights_language":"en"}]},"item_10_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"author"}]},"item_10_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0953-8178","subitem_source_identifier_type":"PISSN"}]},"item_1615787544753":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Takeuchi, Yoshiko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"68545","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nishikawa, Hiroyoshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"68546","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-08-01"}],"displaytype":"detail","filename":"s1-ln234847841682381206-1939656818Hwf-2035235115IdV16389160123484784PDF_HI0001.pdf","filesize":[{"value":"1.2 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"s1-ln234847841682381206-1939656818Hwf-2035235115IdV16389160123484784PDF_HI0001.pdf ファイル公開：2017/08/01","objectType":"fulltext","url":"https://nagoya.repo.nii.ac.jp/record/23126/files/s1-ln234847841682381206-1939656818Hwf-2035235115IdV16389160123484784PDF_HI0001.pdf"},"version_id":"296797fd-c86c-4c05-a3ce-25166142d2ee"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"immune suppression","subitem_subject_scheme":"Other"},{"subitem_subject":"immune checkpoint inhibitors","subitem_subject_scheme":"Other"},{"subitem_subject":"Treg-targeted therapy","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Roles of regulatory T cells in cancer immunity","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Roles of regulatory T cells in cancer immunity","subitem_title_language":"en"}]},"item_type_id":"10","owner":"1","path":["501"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2017-01-05"},"publish_date":"2017-01-05","publish_status":"0","recid":"23126","relation_version_is_last":true,"title":["Roles of regulatory T cells in cancer immunity"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-01-16T05:05:53.915865+00:00"}